Metabolic Communication by SGLT2 Inhibition

Area of Science:

• Metabolomics
• Proteomics
• Microbiome Research

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer cardioprotective and nephroprotective benefits.
• The precise mechanisms underlying these protective effects remain incompletely understood.

Purpose of the Study:

• To elucidate the primary molecular and metabolic effects of SGLT2 inhibitors.
• To investigate SGLT2 inhibitor actions independent of disease-related changes using multi-omics analysis.

Main Methods:

• Integrated proteomics, phosphoproteomics, and metabolomics in diabetic and non-diabetic mice treated with SGLT2 inhibitors.
• Analysis of multiple organs and body fluids after one week of treatment.
• In vitro fermentation studies with human gut microbiota.

Main Results:

• SGLT2 inhibitors induced significant proteomic changes in kidneys, reducing proximal tubule glucotoxicity and apical transporter activity.
• Effects were observed in white adipose tissue (lipolysis) and notably the gut microbiome, decreasing uremic toxin precursors.
• Reduced circulating p-cresol sulfate levels were confirmed, with direct impact on engineered heart tissue function.

Conclusions:

• SGLT2 inhibitors mitigate uremic toxin production by the gut microbiome, lessening the renal detoxification burden.
• Combined with direct renal effects, this establishes a metabolic foundation for SGLT2 inhibitor-mediated kidney and heart protection.
• Findings highlight the gut microbiome's role in SGLT2 inhibitor efficacy.